Actively Recruiting
NKG2D-CAR-NK92 Cells Immunotherapy for Solid Tumors
Led by Henan Medical University · Updated on 2025-04-10
20
Participants Needed
1
Research Sites
165 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this clinical investigation is to evaluate the safety and effects of NKG2D-CAR-NK92 infusions in the treatment of relapsed/refractory solid tumors.
CONDITIONS
Official Title
NKG2D-CAR-NK92 Cells Immunotherapy for Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 75 years, male or female
- Histopathology confirmed malignant tumors including breast, lung, gastric, ovarian, cervical, renal cancers, malignant melanoma, osteosarcoma, or lymphoma
- Expected survival time of at least 3 months
- Disease must be measurable according to guidelines
- Failed or unwilling to receive third-line treatment
- ECOG performance status of 0 to 2
- Last cytotoxic drug, radiotherapy, or surgery at least 4 weeks prior
- Adequate blood counts and liver and kidney function within specified limits
- Women of childbearing age must have a negative pregnancy test within 7 days and use contraception during trial and for 3 months after
- Written informed consent before enrollment
- Tumors confirmed positive for MICA/B by pathology and histology
You will not qualify if you...
- Other malignancies diagnosed within the last 5 years except certain cured cancers
- Brain metastases with symptoms or symptom control less than 3 months
- Active or severe autoimmune diseases or congenital immunodeficiency
- Serious infections or other serious underlying medical conditions
- Active hepatitis B or C infection
- History of severe allergic reactions to biological products including penicillin
- Drug abuse or medical, psychological, or social conditions interfering with study participation
- Participation in another clinical trial within 4 weeks
- Cell or gene therapy within the previous 1 month
- History of immunodeficiency including HIV or organ transplantation
- Clinical or laboratory abnormalities or compliance issues deemed unsuitable by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The first Affiliated Hospital of Xinxiang Medical University
Xinxiang, Henan, China, 453000
Actively Recruiting
Research Team
W
Wuling Zhu
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here